|
|
Post by imz72 on Jun 10, 2016 4:00:32 GMT
Wotton strikes again....ASX , CYP , Cynata Thereputics newest board member. The press talks him up for what he did with Ocat. The company is about MSC's and multiplying them. 's PR about Paul Wotton's appointment: www.irasia.com/listco/au/cynata/press/p160609.htmCynata's market cap is only $26.55 million AUD (translates to less than $20 million USD). |
|
|
|
Post by sundog on Jul 21, 2016 14:55:02 GMT
Research With Retinal Cells Derived From Stem Cells for Myopic Macular Degeneration
This study has been withdrawn prior to enrollment.
(Study to be revised. Future plans to be determined.)
Sponsor:
University of California, Los Angeles
Collaborator:
Ocata Therapeutics
Information provided by (Responsible Party):
Steven Schwartz, University of California, Los Angeles
ClinicalTrials.gov Identifier:
NCT02122159
First received: April 1, 2014
Last updated: July 14, 2016
Last verified: July 2016
History of Changes
Full Text View
Tabular View
No Study Results Poste .............................see ya Schwartz..................any "new" news on Kukkido's & Co. Quest?
|
|
|
|
Post by morangie777 on Jul 21, 2016 16:13:05 GMT
|
|
|
|
Post by selluwud on Aug 5, 2016 11:39:43 GMT
Does anyone find it odd that there has been virtually no news concerning the therapies OCATA had in clinical trials? The AMD & SMD trials, MSC dog trials, platelet & blood manufacturing etc. Maybe Astellas is keeping everything under wraps until after all the dissenting OCATA shareholders' lawsuits are settled. To bring forth proof of value to the therapies would only increase the value of the claims..........maybe?? Otherwise I find it disheartening to think I had so much belief in Lanza's endeavors to only find out they weren't viable.
|
|
|
|
Post by vzveteran on Aug 5, 2016 11:55:41 GMT
Does anyone find it odd that there has been virtually no news concerning the therapies OCATA had in clinical trials? The AMD & SMD trials, MSC dog trials, platelet & blood manufacturing etc. Maybe Astellas is keeping everything under wraps until after all the dissenting OCATA shareholders' lawsuits are settled. To bring forth proof of value to the therapies would only increase the value of the claims..........maybe?? Otherwise I find it disheartening to think I had so much belief in Lanza's endeavors to only find out they weren't viable. I'm thinking the same thing. |
|
|
|
Post by actcrazy on Aug 5, 2016 14:09:32 GMT
Yep...any news from our hero dissenters ? Lanza has talked briefly about cloning and the rest is kinda quiet. ALPMY volume has picked up considerably the past month. Disclosure; I have shares.
|
|
|
|
Post by vzveteran on Aug 5, 2016 19:51:58 GMT
Yep...any news from our hero dissenters ? Lanza has talked briefly about cloning and the rest is kinda quiet. ALPMY volume has picked up considerably the past month. Disclosure; I have shares. Have you signed with an atty yet? |
|
|
|
Post by actcrazy on Aug 6, 2016 3:26:43 GMT
Yep...any news from our hero dissenters ? Lanza has talked briefly about cloning and the rest is kinda quiet. ALPMY volume has picked up considerably the past month. Disclosure; I have shares. Have you signed with an atty yet? No. to be clear, I have no more OCAT. I was disclosing that I own a little ALPMY. Best of luck to all still fighting for appraisal justice. Keeping positive thoughts for all. I believe Astellas has some surprises up their sleeve. |
|
|
|
Post by mmeyrow on Aug 8, 2016 17:29:56 GMT
www.nature.com/articles/srep29784This deals with developing photo-receptor cells in pre-clinical tests by Astellas - don't know if anyone listed this. I have a small position in Astellas and it is up about 25%
|
|
|
|
Post by runcaly on Jan 10, 2017 20:17:34 GMT
Something new from our old friends.
They are still working ...
newsroom.astellas.us/feature-stories?item=982
astellas.com/en/ir/ar2016/feature/index.html
|
|
